SWOT Analysis: HER2 Borderline Resolver: Multi-Omics Reflex Test for Equivocal Breast Biopsies
A reflex multi-omics test for breast biopsies with equivocal HER2 results, integrating genomic, proteomic, and transcriptomic readouts from one FFPE block to give a clear HER2-driver call that decides trastuzumab/pertuzumab eligibility.
The SWOT analysis reveals a high-value clinical niche where multi-omics can resolve diagnostic ambiguity that current IHC/FISH standards cannot. While the technical integration of three omics layers from FFPE blocks presents a significant operational hurdle, the shift toward HER2-low therapy expansion creates a strong market pull for a definitive 'resolver' test.
Strengths3
Weaknesses3
Opportunities3
Threats3
Essential for evaluating the internal technical advantage of multi-omics integration against the external threat of evolving standard-of-care testing. · Generated 2026-10-17 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated